Cargando…
Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R)-CHOP
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Fondazione Ferrata Storti
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543194/ https://www.ncbi.nlm.nih.gov/pubmed/36815369 http://dx.doi.org/10.3324/haematol.2022.282126 |
| _version_ | 1785114246629031936 |
|---|---|
| author | Bewarder, Moritz Kaddu-Mulindwa, Dominic Kos, Igor Age Lesan, Vadim Held, Gerhard Poeschel, Viola Thurner, Lorenz Bittenbring, Joerg Thomas Schmitz, Norbert Truemper, Lorenz Pfreundschuh, Michael Christofyllakis, Konstantinos Loeffler, Markus Altmann, Bettina Ziepert, Marita |
| author_facet | Bewarder, Moritz Kaddu-Mulindwa, Dominic Kos, Igor Age Lesan, Vadim Held, Gerhard Poeschel, Viola Thurner, Lorenz Bittenbring, Joerg Thomas Schmitz, Norbert Truemper, Lorenz Pfreundschuh, Michael Christofyllakis, Konstantinos Loeffler, Markus Altmann, Bettina Ziepert, Marita |
| author_sort | Bewarder, Moritz |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10543194 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Fondazione Ferrata Storti |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-105431942023-10-03 Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R)-CHOP Bewarder, Moritz Kaddu-Mulindwa, Dominic Kos, Igor Age Lesan, Vadim Held, Gerhard Poeschel, Viola Thurner, Lorenz Bittenbring, Joerg Thomas Schmitz, Norbert Truemper, Lorenz Pfreundschuh, Michael Christofyllakis, Konstantinos Loeffler, Markus Altmann, Bettina Ziepert, Marita Haematologica Letter to the Editor Fondazione Ferrata Storti 2023-02-23 /pmc/articles/PMC10543194/ /pubmed/36815369 http://dx.doi.org/10.3324/haematol.2022.282126 Text en Copyright© 2023 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
| spellingShingle | Letter to the Editor Bewarder, Moritz Kaddu-Mulindwa, Dominic Kos, Igor Age Lesan, Vadim Held, Gerhard Poeschel, Viola Thurner, Lorenz Bittenbring, Joerg Thomas Schmitz, Norbert Truemper, Lorenz Pfreundschuh, Michael Christofyllakis, Konstantinos Loeffler, Markus Altmann, Bettina Ziepert, Marita Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R)-CHOP |
| title | Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R)-CHOP |
| title_full | Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R)-CHOP |
| title_fullStr | Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R)-CHOP |
| title_full_unstemmed | Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R)-CHOP |
| title_short | Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R)-CHOP |
| title_sort | impact of vincristine dose reduction on outcomes of patients with aggressive b-cell lymphoma treated with (r)-chop |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543194/ https://www.ncbi.nlm.nih.gov/pubmed/36815369 http://dx.doi.org/10.3324/haematol.2022.282126 |
| work_keys_str_mv | AT bewardermoritz impactofvincristinedosereductiononoutcomesofpatientswithaggressivebcelllymphomatreatedwithrchop AT kaddumulindwadominic impactofvincristinedosereductiononoutcomesofpatientswithaggressivebcelllymphomatreatedwithrchop AT kosigorage impactofvincristinedosereductiononoutcomesofpatientswithaggressivebcelllymphomatreatedwithrchop AT lesanvadim impactofvincristinedosereductiononoutcomesofpatientswithaggressivebcelllymphomatreatedwithrchop AT heldgerhard impactofvincristinedosereductiononoutcomesofpatientswithaggressivebcelllymphomatreatedwithrchop AT poeschelviola impactofvincristinedosereductiononoutcomesofpatientswithaggressivebcelllymphomatreatedwithrchop AT thurnerlorenz impactofvincristinedosereductiononoutcomesofpatientswithaggressivebcelllymphomatreatedwithrchop AT bittenbringjoergthomas impactofvincristinedosereductiononoutcomesofpatientswithaggressivebcelllymphomatreatedwithrchop AT schmitznorbert impactofvincristinedosereductiononoutcomesofpatientswithaggressivebcelllymphomatreatedwithrchop AT truemperlorenz impactofvincristinedosereductiononoutcomesofpatientswithaggressivebcelllymphomatreatedwithrchop AT pfreundschuhmichael impactofvincristinedosereductiononoutcomesofpatientswithaggressivebcelllymphomatreatedwithrchop AT christofyllakiskonstantinos impactofvincristinedosereductiononoutcomesofpatientswithaggressivebcelllymphomatreatedwithrchop AT loefflermarkus impactofvincristinedosereductiononoutcomesofpatientswithaggressivebcelllymphomatreatedwithrchop AT altmannbettina impactofvincristinedosereductiononoutcomesofpatientswithaggressivebcelllymphomatreatedwithrchop AT ziepertmarita impactofvincristinedosereductiononoutcomesofpatientswithaggressivebcelllymphomatreatedwithrchop |